Disulfidptosis, a new form of programmed cell death, plays a role in multiple types of cancer. However, research on disulfidptosis in glioma is lacking. A disulfidptosis‐associated risk score was constructed using Cox regression modelling, while LASSO regression was applied for feature selection. To explore the relationship between the risk score and the immune microenvironment, we employed CIBERSORT, ssGSEA and ESTIMATE algorithms. Additionally, wet lab experiments were conducted to validate the functional role of the key disulfidptosis gene RPN1, demonstrating its ability to promote glioma cell proliferation and migration. Disulfidptosis genes were significantly upregulated in gliomas, influencing clinical features and survival. The risk score effectively predicted OS and varied among clinical subgroups. High‐risk scores correlated with tumour growth, invasion and immunosuppression. Patients with different risk scores showed distinct immune cell infiltration patterns. Most immune checkpoints and chemokines were positively associated with risk scores. Laboratory findings confirmed that RPN1 significantly promoted glioma cell proliferation and migration. Disulfidptosis‐based risk assessment stratifies glioma prognosis and reveals immune microenvironment characteristics, offering insights for personalised treatment strategies.

Intracerebral hemorrhage (ICH) is a highly fatal form of stroke for which there are limited effective treatments. Cuproptosis, a newly discovered type of programmed cell death, has not yet been investigated in relation to ICH. Thus, the main goal of our study was to investigate the involvement of cuproptosis-related genes (CRGs) in predicting the early outcomes of ICH. We used datasets GSE228222 and GSE200575 from the Gene Expression Omnibus (GEO) database to identify and analyze differentially expressed genes (DEGs) between ICH samples and control samples from mice. From this analysis, seven cuproptosis-related DEGs (CuDEGs) were identified: pyruvate dehydrogenase E1 component subunit alpha (Pdha1), glutaminase (Gls), dihydrolipoamide dehydrogenase (Dld), pyruvate dehydrogenase E1 component subunit beta (Pdhb), dihydrolipoamide S-acetyltransferase (Dlat), metal regulatory transcription factor 1(Mtf1), and solute carrier family 31 member 1 (Slc31a1). Pathway enrichment analysis connected these genes to metabolic pathways, while immune cell infiltration analysis revealed increased macrophages and naive CD8 T cells alongside reduced NK resting cells and CD4 T cells in ICH samples. Verification through qRT-PCR and immunohistochemistry demonstrated a lower expression of CuDEGs in ICH samples. Of particular note, Gls, a gene significantly linked to both cuproptosis and immune regulation, exhibited reduced expression, possibly reflecting a protective response to limit glutamate production and mitigate neuronal damage. In summary, Gls emerges as a promising target for improving ICH outcomes by regulating cuproptosis and immune activity. This research provides novel insights into the molecular processes involved in ICH and suggests potential therapeutic approaches.

Background: Glioblastoma multiforme is the most common primary intracranial tumor, with a high degree of malignancy, poor therapeutic effect, and poor prognosis. According to previous studies, CHI3L1 and EMP3 are two independent tumor predictors that are of great significance for the prognostic prediction of other tumors, and their expression levels may be related to the prognosis of glioma patients. Methods: using Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), the Chinese Glioma Genome Atlas (CGGA), cBioPortal, LinkedOmics, and other databases, 693 glioma patients were screened to analyze the relationship between EMP3 and CHI3L1 expression and prognosis in glioma patients. Results: low-grade glioma patients with a low expression of EMP3/CHI3L1 had a better prognosis, and the combination of EMP3/CHI3L1 is a new predictor for glioma patients. Conclusion: We used the TCGA and CGGA databases to analyze the effect of EMP3 and CHI3L1 expression on the prognosis of glioma patients and their correlation with gene expression using bioinformation analysis. The results showed that low-grade glioma patients with a low expression of EMP3 and CHI3L1 had a better prognosis, and EMP3 and CHI3L1 co-expression genes were correlated. The combination of these two factors could be a new prognostic index for glioma patients.

LINC00324 is a long-stranded non-coding RNA, which is aberrantly expressed in various cancers and is associated with poor prognosis and clinical features. It involves multiple oncogenic molecular pathways affecting cell proliferation, migration, invasion, and apoptosis. However, the expression, function, and mechanism of LINC00324 in glioma have not been reported. We assessed the expression of LINC00324 of LINC00324 in glioma patients based on data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to identify pathways involved in LINC00324-related glioma pathogenesis. Based on our findings, we observed differential expression of LINC00324 between tumor and normal tissues in glioma patients. Our analysis of overall survival (OS) and disease-specific survival (DSS) indicated that glioma patients with high LINC00324 expression had a poorer prognosis compared to those with low LINC00324 expression. By integrating clinical data and genetic signatures from TCGA patients, we developed a nomogram to predict OS and DSS in glioma patients. Gene set enrichment analysis (GSEA) revealed that several pathways, including JAK/STAT3 signaling, epithelial-mesenchymal transition, STAT5 signaling, NF-κB activation, and apoptosis, were differentially enriched in glioma samples with high LINC00324 expression. Furthermore, we observed significant correlations between LINC00324 expression, immune infiltration levels, and expression of immune checkpoint-related genes (HAVCR2: r = 0.627, P = 1.54e-77; CD40: r = 0.604, P = 1.36e-70; ITGB2: r = 0.612, P = 6.33e-7; CX3CL1: r = -0.307, P = 9.24e-17). These findings highlight the potential significance of LINC00324 in glioma progression and suggest avenues for further research and potential therapeutic targets. Indeed, our results confirm that the LINC00324 signature holds promise as a prognostic predictor in glioma patients. This finding opens up new possibilities for understanding the disease and may offer valuable insights for the development of targeted therapies.

The aim of this study was to retrospectively analyze the clinical data of 24 patients with small vestibular schwannomas, explore the surgical outcomes, and summarize the surgical experience. Patients with small vestibular schwannomas who underwent surgery between January 2019 and December 2022 at the Department of Neurosurgery of the First Affiliated Hospital of Soochow University were included. Clinical data from all patients were collected and analyzed. Total tumor resection was achieved in all patients. Microscopic surgery alone was sufficient for complete resection in 7 patients, while the remaining 17 patients required combined microscopic and endoscopic approaches for complete removal. At the final follow-up, 16 patients maintained preoperative facial nerve function, 6 patients experienced improvement, while 2 patients experienced deterioration. And there were 13 patients maintained preoperative hearing function, 9 patients experienced improvement, while 2 patients experienced deterioration. Compared with microscopic resection alone, there was no significant difference in the Facial nerve function and Hearing function of patients underwent microscopic and endoscopic resection. During the follow-up period, all patients showed favorable prognosis without disease progression. Compared with microscopic surgery, the microscopic with endoscopic surgery for small vestibular schwannomas lead to the better results in the degree of tumor resection, with no difference in functional protection.

Aim: Glioma, the most common primary brain tumor, is known for its poor prognosis, limited treatment success, and high level of aggressiveness. Although cuproptosis-related genes have been linked to outcomes in other cancers, their role in glioma is still not well understood. Methods: By leveraging the Cancer Genome Atlas (TCGA) and additional databases, we conducted Cox regression and Kaplan-Meier analysis to determine the predictive importance of cuproptosis-related genes in individuals with glioma. By utilizing data from Gene Expression Omnibus (GEO) and other relevant databases, we examined how the expression of cuproptosis-associated genes correlates with immune cell infiltration, immunological checkpoint status, pathological stage, and histological grade. Additionally, we analyzed the connection between gene expression linked to cuproptosis and the prognosis in glioma patients. Results: Our newly developed cuproptosis-based glioma predictive model demonstrated promising prediction performance. Additionally, we identified glutaminase (GLS) in glioblastoma as a potential novel diagnostic indicator for glioma patients. Conclusion: GLS holds the potential to provide novel perspectives on cancer management and serve as a valuable diagnostic predictor for glioma patients.